

SWIXX AND KYOWA KIRIN ENTER INTO PARTNERSHIP FOR RARE DISEASE MEDICINES PORTFOLIO IN POLAND

SWIXX ANNOUNCEMENT NO. 48

October 10th, 2022

Baar, Switzerland – Swixx BioPharma AG of Baar, Switzerland, announced today the signature of a Promotion and Distribution Agreement with Kyowa Kirin Services, Ltd. and Kyowa Kirin Holdings B.V., both of which are wholly-owned subsidiaries of Kyowa Kirin Co., Ltd. of Tokyo, Japan. Under the Agreement, Kyowa Kirin has appointed Swixx to exclusively market, promote and distribute CRYSVITA® (burosumab) and POTELIGEO® (mogamulizumab) in Poland.

Burosumab is a recombinant human monoclonal (IgG1) antibody that binds to and inhibits the activity of fibroblast growth factor 23 (FGF23). Burosumab is indicated for the treatment of X-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. X-linked hypophosphataemia is a hereditary disorder characterized by low levels of phosphate in the blood. Phosphate is essential to build bones and teeth and to maintain their strength, so patients may develop rickets, osteomalacia and other clinical consequences and growth problems.¹ In August 2022, the European Commission approved burosumab of FGF23-related hypophosphataemia in Tumour-Induced Osteomalacia (TIO) associated with phosphaturic mesenchymal tumours (PMTs) that cannot be curatively resected or localized in children and adolescents aged 1 to 17 years and in adults.¹

Mogamulizab is a monoclonal antibody that selectively binds to CC chemokine receptor 4 (CCR4) and is indicated for the treatment of adult patients with mycosis fungoides or Sézary syndrome who have received at least one prior systemic therapy. Both mycosis fungoides and Sezary syndrome belong to a group of rare cancers of blood cells (cutaneous T-cell lymphomas) that affect mainly the skin.²

“We are honored to partner with Kyowa Kirin for the commercialization of Crysvida and Poteligeo in Poland,” commented Swixx’s COO, Dr. Dezso Martha. “Both of these orphan medicines bring important advancements to the treatment of both rare metabolic diseases and rare cancers – and in medical areas where there are limited or no alternative therapeutic options. We value the opportunity afforded by this new partnership with Kyowa Kirin because it reinforces Swixx’s presence in rare and hemato-onco diseases and allows us to provide access for Polish patients to the innovative, modern medicines of Kyowa Kirin.”

“Kyowa Kirin is pleased to be able to partner with Swixx to ensure people in Poland will have access to the medicines needed to treat these rare diseases,” added Abdul Mullick, President of Kyowa Kirin International. “Our purpose is to make people smile and knowing that we are living our purpose by helping to meet the unmet needs in Poland in CTCL, XLH and TIO through this important partnership with Swixx is another critical step on our journey as a company. We look forward to seeing the impact Swixx will have for these patients.”

“The agreement with Kyowa Kirin marks an important evolution for our Polish organization,” commented Swixx’s General Manager in Poland, Dr. Michal Opuchlik. “By leveraging our Polish team’s strong presence in rare disease and hemato-oncology, we will work diligently in close collaboration with Kyowa Kirin to bring both these medicines to Polish patients in need. It is marvelous for all of us at Swixx to have this opportunity to improve patient outcomes in Poland.”

About Swixx BioPharma AG

Swixx operates fully owned subsidiaries across Central and Eastern Europe, Greece, Russia and several Eurasian Economic Union countries plus Moldova and Uzbekistan. With over 1100 employees and sales likely to exceed 700M Euros in 2022, Swixx has swiftly evolved into the largest and fastest-growing dedicated agent for biopharma and self-medication innovative companies in CEE and Russia. The company has gathered outstanding rare disease, oncology-haematology, specialty, and self-medication talent under one roof. For more information about Swixx, please visit:

www.swixxbiopharma.com

Contact: Vedrana Sokac Brataljenovic, Public Affairs Director, Swixx BioPharma AG

vedrana.sokac@swixxbiopharma.com Tel: +385 1 425 6086

References:

¹European Commission. Union Register of medicinal products for human use. Available at: [Union Register of medicinal products - Public health - European Commission \(europa.eu\)](https://ec.europa.eu/health/medicines/union_register_of_medicinal_products/). Last accessed: October 2022.

²European Commission. Union Register of medicinal products for human use. Available at [Union Register of medicinal products - Public health - European Commission \(europa.eu\)](https://ec.europa.eu/health/medicines/union_register_of_medicinal_products/). Last accessed: October 2022.